BELLUS Health Inc (BLU) – Press Releases
-
BELLUS Health Inc. Announces Voting Results from Special Meeting of Shareholders
-
BELLUS Health Inc. Calls Special Shareholders’ Meeting in Connection with GSK Acquisition
-
BELLUS Health Reports First Quarter 2023 Financial Results and Business Highlights
-
BELLUS Health Announces Meeting Updates
-
GSK reaches agreement to acquire late-stage biopharmaceutical company BELLUS Health
-
BELLUS Health Announces Positive Results from its Phase 1 Bioavailability Equivalence Study Evaluating Once-Daily Extended-Release Formulation of Camlipixant in Comparison to Twice-Daily Immediate Rel
-
BELLUS Health Reports Year 2022 Financial Results and Business Highlights
-
BELLUS Health to Participate in the Cowen 43rd Annual Health Care Conference
-
BELLUS Health to Present on the Patient Experience and the Burden of Refractory Chronic Cough at the American Academy of Allergy, Asthma & Immunology Annual Meeting
-
OnCusp Therapeutics Announces Appointment of Robert Forrester and Chau Khuong to Board of Directors
-
BELLUS Health Reports Third Quarter 2022 Financial Results and Business Highlights
-
BELLUS Health to Participate in Two Upcoming Healthcare Investor Conferences
-
BELLUS Health to Present Clinical Data from Phase 2b SOOTHE Trial of BLU-5937 at the CHEST Annual Meeting
-
BELLUS Health to Present at the H.C. Wainwright Global Investment Conference
-
BELLUS Health to Present Clinical Data from Phase 2b SOOTHE Trial of BLU-5937 at the European Respiratory Society International Congress 2022
-
BELLUS Health Reports Second Quarter 2022 Financial Results and Business Highlights
-
BELLUS Health Closes US$153 Million Public Offering of Common Shares in Canada and the United States
-
BELLUS Health Announces Pricing of US$153 Million Public Offering in Canada and the United States
-
BELLUS Health Announces the Launch of a Public Offering of Common Shares in Canada and the United States
-
Bellus Health Announces Positive End-of-Phase 2 Meeting with the FDA and its CALM Phase 3 Program for BLU-5937 in Refractory Chronic Cough
-
BELLUS Health to Participate in the William Blair Biotech Focus Conference
-
BELLUS Health to Participate in the Jefferies Healthcare Conference
-
BELLUS Health Reports First Quarter 2022 Financial Results and Business Highlights
-
BELLUS Health to Present Late-Breaking Clinical Data from the Phase 2b SOOTHE Trial of BLU-5937 at the ATS 2022 International Conference
-
BELLUS Health to Participate in Multiple Upcoming Investor Conferences
-
BELLUS Health to Participate in the Cowen & Co. 42nd Annual Health Care Conference
-
BELLUS Health Reports Year 2021 Financial Results and Business Highlights
-
BELLUS Health Closes US$200 Million Public Offering of Common Shares in Canada and the United States
-
BELLUS Health Announces Pricing of US$200 Million Public Offering in Canada and the United States
-
BELLUS Health Announces the Launch of a Public Offering of Common Shares in Canada and the United States
-
BELLUS Health Announces Positive Topline Results from its Phase 2b SOOTHE Trial of BLU-5937 for the Treatment of Refractory Chronic Cough
-
BELLUS Health Reports Third Quarter 2021 Financial Results and Business Highlights
-
BELLUS Health to Participate in Two Upcoming Healthcare Investor Conferences
-
BELLUS Health Convenes Virtual Analyst Event to Discuss the Chronic Cough Landscape and its Selective P2X3 Antagonist BLU-5937
-
BELLUS Health Announces Completion of Patient Enrollment in SOOTHE Phase 2b Trial for Refractory Chronic Cough and BLUEPRINT Phase 2a Trial for Chronic Pruritus Associated with Atopic Dermatitis
-
BELLUS Health Announces Positive Interim Analysis from the Phase 2b SOOTHE Trial of BLU-5937 in Refractory Chronic Cough
-
BELLUS Health to Present at the H.C. Wainwright Global Investment Conference
-
BELLUS Health to Report Additional RELIEF Data in an Oral Presentation at the European Respiratory Society International Congress 2021
-
BELLUS Health Reports Second Quarter 2021 Financial Results and Business Highlights
-
BELLUS Health to Participate in the Jefferies Virtual Healthcare Conference
-
Morganti & Co., P.L.C. Announces the Filing of a Securities Class Action on Behalf of Investors Who Acquired Bellus Health, Inc.
-
BELLUS Health to Participate in the 2021 RBC Capital Markets Global Healthcare Conference
-
BELLUS Health Reports First Quarter 2021 Financial Results and Business Highlights
-
BELLUS Health to Present at the American Thoracic Society 2021 International Conference
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Bellus Health, Neptune Wellness, Sequential Brands, and CytoDyn and Encourages Investors to Contact the
-
BLU SHAREHOLDER FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff in a Securities Class Action Lawsuit Against BELLUS Health, Inc.
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Bellus Health, Neptune Wellness, Sequential Brands, and CytoDyn and Encourages Investors to Contact the
-
BLU SHAREHOLDER FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff in a Securities Class Action Lawsuit Against BELLUS Health, Inc.
-
BLU SHAREHOLDER FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff in a Securities Class Action Lawsuit Against BELLUS Health, Inc.
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against XL Fleet Corp., Bellus Health, Neptune Wellness, and Sequential Brands and Encourages Investors to Cont
Back to BLU Stock Lookup
